Jefferies Financial Group Inc. Makes New Investment in BeOne Medicines Ltd. – Sponsored ADR $ONC

Jefferies Financial Group Inc. bought a new position in BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 6,200 shares of the company’s stock, valued at approximately $1,884,000.

A number of other large investors have also bought and sold shares of ONC. Leonteq Securities AG purchased a new stake in BeOne Medicines in the fourth quarter worth $35,000. Daiwa Securities Group Inc. purchased a new stake in BeOne Medicines in the second quarter worth $35,000. CWM LLC increased its position in BeOne Medicines by 32.8% in the fourth quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after buying an additional 39 shares during the last quarter. Farther Finance Advisors LLC boosted its position in BeOne Medicines by 21.8% during the fourth quarter. Farther Finance Advisors LLC now owns 218 shares of the company’s stock worth $66,000 after purchasing an additional 39 shares during the period. Finally, EverSource Wealth Advisors LLC bought a new position in BeOne Medicines during the second quarter worth about $68,000. 48.55% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Truist Financial reiterated a “buy” rating and set a $413.00 target price (up from $411.00) on shares of BeOne Medicines in a research report on Thursday, May 7th. Barclays increased their target price on shares of BeOne Medicines from $405.00 to $409.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BeOne Medicines in a research report on Monday, April 20th. Leerink Partners increased their target price on BeOne Medicines from $364.00 to $367.00 and gave the stock an “outperform” rating in a research report on Friday, May 15th. Finally, Wall Street Zen upgraded BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $389.15.

BeOne Medicines Trading Down 0.8%

Shares of ONC opened at $300.01 on Thursday. The business’s 50-day moving average price is $301.85 and its 200-day moving average price is $321.12. BeOne Medicines Ltd. – Sponsored ADR has a twelve month low of $235.57 and a twelve month high of $385.22. The stock has a market cap of $32.92 billion, a PE ratio of 67.12 and a beta of 0.50. The company has a quick ratio of 3.27, a current ratio of 3.64 and a debt-to-equity ratio of 0.20.

BeOne Medicines (NASDAQ:ONC) last announced its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%.The firm had revenue of $1.51 billion for the quarter. On average, equities analysts forecast that BeOne Medicines Ltd. – Sponsored ADR will post 5.65 EPS for the current fiscal year.

Insider Activity

In other news, Director Alessandro Riva sold 212 shares of the business’s stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $309.51, for a total transaction of $65,616.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Margaret Dugan sold 212 shares of the business’s stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $309.60, for a total transaction of $65,635.20. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 1,641 shares of company stock valued at $505,791 over the last 90 days. Company insiders own 6.19% of the company’s stock.

BeOne Medicines Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.